How the Body's Own Opioid Peptides Work Through Different Versions of the Mu Opioid Receptor
Endogenous opioid peptides (enkephalins, dynorphins, β-endorphin) show distinct pharmacological profiles across OPRM1 7TM C-terminal splice variants, with different binding, G-protein activation, and biased signaling patterns.
Quick Facts
What This Study Found
Endogenous opioid peptides show variant-specific pharmacological profiles across OPRM1 7TM C-terminal splice variants, with distinct patterns of receptor binding, G protein activation, and β-arrestin2 recruitment indicating biased signaling.
Key Numbers
Three endogenous opioid families; extensive OPRM1 splice variants; differential interactions affecting pain, reward, emotion.
How They Did This
Review of pharmacological studies examining endogenous opioid peptide interactions with mouse, rat, and human OPRM1 7TM C-terminal variants. Covers binding affinity, G protein activation, β-arrestin2 recruitment, and biased signaling.
Why This Research Matters
Understanding how natural opioid peptides signal differently through receptor variants could reveal why some pathways produce pain relief without addiction, potentially guiding the development of safer opioid alternatives.
The Bigger Picture
The opioid crisis has driven intense interest in understanding opioid receptor biology. The body's own opioid peptides provide pain relief without the devastating addiction seen with synthetic opioids — understanding why could be the key to developing safer pain medications.
What This Study Doesn't Tell Us
Review of primarily in vitro pharmacological data. Translation of receptor-level signaling differences to in vivo analgesic and addictive effects is complex. Species differences between mouse, rat, and human variants add complexity.
Questions This Raises
- ?Can biased agonism at specific OPRM1 splice variants be exploited to develop non-addictive analgesics?
- ?Which splice variants are most relevant to clinical pain and addiction pathways?
- ?Could endogenous opioid peptide-mimetic drugs provide pain relief without respiratory depression?
Trust & Context
- Key Stat:
- Biased signaling endogenous opioid peptides show different β-arrestin2 vs. G-protein activation across OPRM1 splice variants
- Evidence Grade:
- Comprehensive review of in vitro pharmacological studies across species. Provides important mechanistic framework but clinical translation of biased signaling concepts is still evolving.
- Study Age:
- Published in 2021. Biased agonism at opioid receptors remains a major focus of analgesic drug development.
- Original Title:
- Endogenous Opioid Peptides and Alternatively Spliced Mu Opioid Receptor Seven Transmembrane Carboxyl-Terminal Variants.
- Published In:
- International journal of molecular sciences, 22(7) (2021)
- Authors:
- Abrimian, Anna, Kraft, Tamar, Pan, Ying-Xian
- Database ID:
- RPEP-05254
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are endogenous opioid peptides?
These are natural painkillers produced by our own bodies — enkephalins, dynorphins, and β-endorphin. They activate the same receptors as morphine and other opioid drugs but generally without causing addiction.
What is biased signaling?
When a molecule activates a receptor, it can trigger multiple downstream pathways. 'Biased' signaling means some molecules preferentially activate certain pathways over others — potentially producing pain relief without the addictive or respiratory depression effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05254APA
Abrimian, Anna; Kraft, Tamar; Pan, Ying-Xian. (2021). Endogenous Opioid Peptides and Alternatively Spliced Mu Opioid Receptor Seven Transmembrane Carboxyl-Terminal Variants.. International journal of molecular sciences, 22(7). https://doi.org/10.3390/ijms22073779
MLA
Abrimian, Anna, et al. "Endogenous Opioid Peptides and Alternatively Spliced Mu Opioid Receptor Seven Transmembrane Carboxyl-Terminal Variants.." International journal of molecular sciences, 2021. https://doi.org/10.3390/ijms22073779
RethinkPeptides
RethinkPeptides Research Database. "Endogenous Opioid Peptides and Alternatively Spliced Mu Opio..." RPEP-05254. Retrieved from https://rethinkpeptides.com/research/abrimian-2021-endogenous-opioid-peptides-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.